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Abstract: Recent studies indicate the significant role of apoptosis and the genes that control it in the process 
of carcinogenesis. Apoptosis or programmed cell death is a complex process that controls cell proliferation 
and maintenance of accounting for the necessary balance in the body. Disturbances of apoptotic signalling 
pathways directly lead to the development and progression of cancer. This also applies to pancreatic cancer, 
which is characterized by poor prognosis and resistance to treatment. In recent years progress has been made 
concerning the complex pathways of apoptosis, which allowed the development of new therapeutic strategies. 
This article reviews current knowledge on apoptosis pathways and their role in treatment of pancreatic cancer. 
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Introduction
Apoptosis or programmed cell death is a physiological process, which leads to elimi-
nation from the body of harmful, unnecessary or damaged cells [1, 2]. The balance be-
tween the processes of proliferation and apoptosis is essential to maintain homeostasis 
in the body [3]. 
Recent studies concerning cancer biology have shown that apoptosis and the genes 
which control it have a significant influence on the processes of carcinogenesis [4]. In 
addition, deregulation of apoptosis pathways contribute to the generation of resistance to 
currently used therapy [5, 6]. Evasion of apoptosis is one of the important characteristics 
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of cancer, promotes tumor growth and progression of metastases [7]. Therefore, a bet-
ter understanding of the regulation of apoptosis in cancer cells may contribute to more 
effective treatments (Fig. 2) [8].
Pancreatic cancer is a cancer of the increasing incidence of survival 5 years not ex-
ceeding 5% [9]. Insufficient effectiveness of current treatment a regimen contributes to 
poor prognosis and is one of the most important challenges in the field of oncology [10].
Currently, considerable progress in clarifying the molecular mechanisms of pan-
creatic cancer. It was shown that the development of pancreatic cancer is due to the 
presence of numerous genetic abnormalities and disorders of the genes responsible for 
the regulation of apoptosis [11]. The accumulation of mutations leading to changes in 
the morphology of epithelial ductal and tumor development [12]. In pancreatic cancer 
is well documented high incidence of p53 gene mutations and gene family Bcl-2 (B-cell 
lymphoma 2) [11, 13].
Apoptosis pathways
The main pathways leading to apoptosis can be induced by a signal from the outside, 
which is associated with activation of membrane death receptors. The second way is 
called the p53 pathway proceeds with the participation of mitochondria and is referred 
to as internal [14]. The DNA damaging agents and activating apoptosis replace the ther-
mal stress, oxidative stress, lack or deficiency of growth factors. To internal regulators of 
apoptosis are included among other proteins belonging to the Bcl-2 family [11]. 
Activation of the external route begins with the stimulation of receptors “death 
signal” (Fig. 1) which takes place by attaching to specific ligands [11, 14]. Membrane 
death receptors belong to the TNF (tumor necrosis factor) receptor superfamily, they also 
include TNF-R1 (tumor necrosis factor receptor), Fas (Apo-1/CD95) and receptors for 
TRAIL (TNF related apoptosis inducing ligand). These receptors are activated by their 
natural ligands (TNFα, FasL, factor TRAIL) [8, 15]. A unique feature is the presence of 
death receptor intracellular domain DD (death domain). As a result of ligand-binding 
receptor oligomerization occurs, then it is linked to a protein FADD (Fas-associated 
death domain protein) and procaspase 8 or 10 thereby forming a complex of DISC 
(death-inducing signaling complex) [8, 14, 15]. The consequence of these processes is the 
activation procaspase 8, which is a direct activator of caspase 3. It is postulated that the 
role of caspase-10 may be important in cells which lack caspase-8 [16].
In the cells of “type I” apoptosis pathway is exclusively external, but in other “type 
II” signal amplification occurs through mitochondria. This process is associated with 
proteolysis of the proapoptotic protein Bcl-2 family, namely protein Bid (BH3 in- ter-
acting domain) by caspase 8 [15]. This protein is in an active form tBid (truncated Bid) 
moves to the mitochondria, where it comes to its integration with the inner mitochon-
drial membrane [17–19]. 
63Therapeutic importance of apoptosis pathways in pancreatic cancer
Fig. 1. Simplified diagram of the process of apoptosis in the two pathways connecting by Bid protein.
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Activation of the internal (Fig. 1) route is associated with the outflow of cytochrome c 
(cyt c), which induces the formation of a complex called apoptosome composed of cyt c, 
procaspase 9, ATP and the cytosolic protein Apaf 1 (Apoptotic protease activating factor 
1). The formation of the complex is required for activation procaspase 9, which acts as 
a direct activator of caspase 3 [14, 15]. The mitochondrial proteins are released by the 
IAP (Binding Protein with Low PI) antagonist inhibitor of apoptosis and protein AIF 
(Apoptosis Inducing Factor) [8].
Morphological processes are described as structural changes in the cell. This leads 
to loss of intracellular water, the concentration of the cytoplasm and cell size reduction. 
A characteristic feature of apoptosis is nuclear chromatin condensation and the disappear-
ance of nuclear membrane, and the next stage of the fragmentation of the nucleus [2, 11].
The role of apoptosis pathways in the treatment of pancreatic cancer
Death receptors
One of the factors that trigger the process of apoptotic cell death is death receptor 
activation. Deregulation of this pathway may contribute to tumor growth and tumor 
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development [14]. Therefore, these receptors appear to be a natural goal for molecular 
anticancer drugs [20]. In the case of pancreatic cancer drew attention to the receptor 
Fas (Apo-1/CD95), TRAIL-R1, TRAIL-R2 and their ligands [15]. 
Arrangements for the Fas receptor expression in pancreatic cancer are conflicted, 
which may suggest that cancer cells may avoid apoptosis by downregulation of Fas re-
ceptor. In addition, demonstrated that FAP1 (Fas-associated phosphatase 1) can block 
the function of Fas. Cell lines resistant to Fas-dependent apoptosis show a strong over-
expression of FAP-1, which was also observed in pancreatic cancer cells. Modulation 
of the enzymatic activity of FAP-1 can be used in the search for effective treatment of 
pancreatic cancer [15, 21]. 
Promising candidate because of its low toxicity is TRAIL, however, most pancreatic 
cancer cell lines show resistance to it. Sensitivity to TRAIL may be increased by com-
bination therapy with other chemotherapeutic agents. It was observed that TRAIL has 
a higher antitumor activity in combination with gemcitabine [8, 22]. Because of the 
resistance to TRAIL is designed for this type of selective receptor variants of recombi-
nant TRAIL. Following an exchange of several amino acids in the native recombinants 
obtained selectivity for TRAIL-R1 and TRAIL-R2. In this way, managed to obtain 
a human agonistic monoclonal antibodies specific for TRAIL receptors. Antibodies have 
proven to be effective as monotherapy and combination therapy [23].
It should be noted that not all receptors of this group have a death domain (DD). 
Some receptors for TRAIL (TRAIL-R3, TRIAL-R4, DcR3) is a so-called “decoy receptors”. 
Joining factor TRAIL by these receptors does not induce apoptosis pathway activation [22].
In vitro studies have also shown an increased incidence of metastases, suggesting 
that in addition to the role of pro-apoptotic TRAIL may act as features associated with 
the mechanisms of tumor cell resistance to apoptosis and activation of a cascade of 
survival [8, 22].
Inhibitors of apoptosis proteins (IAP)
Protein IAP (Inhibitor of Apoptosis Proteins) are important defense against cancer cell 
death by apoptosis, also perform important functions during cell division. For IAP pro-
teins are: NAIP (Neural Apoptosis Inhibitor Protein), XIAP (X-linked IAP), survivin, Bruce 
(Apollon), livin (ML-IAP) and cIAP-1 (cellular inhibitor of apoptosis-1), cIAP-2 (cellular 
inhibitor of apoptosis-2). Most of them have the ability to directly bind and inhibit caspase 
3, 7, and 9 [8, 22, 24]. IAP proteins may also act as ubiquitin ligases and in this way to 
the degradation of caspases [25]. Membership of a protein depends on the presence of 
IAP BIR (baculoviral IAP-repeat) domains required for interaction with caspases [15]. 
High expression of IAP proteins (IAP, cIAP-1, cIAP-2, survivin, livin) was observed 
in pancreatic cancer cells [26]. The IAP protein has the strongest anti-apoptotic activity 
of XIAP, which has the ability to directly block the caspases. In many cells, including 
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pancreatic cancer have a reduced level of a negative regulator of XIAP, namely XAF-1 
(XIAP-associated factor 1), regarded as a tumor suppressor gene product. In multivariate 
analysis, expression of XAF-1 proved to be a significant predictor of survival among 
patients. It has been observed since that low levels of XAF-1 correlates with poor prog-
nosis in patients with pancreatic cancer [27]. 
IAP proteins are negatively controlled at several levels including the mitochondrial 
Smac/DIABLO (Second Mitochondria-derived Activator of Caspases/Direct IAP Binding 
Protein with Low PI) to prevent inhibition of caspase 3 and 9, which sensitizes cancer 
XIAP, which binds peptides of Smac/DIABLO can be used as a target for the design of 
compounds that inhibit the activity of XIAP [28]. 
For compounds that inhibit XIAP are synthetic, small molecule inhibitors to sen-
sitize cancer treatment. XIAP is an inhibitor of benzoquinone Embelin, a natural com-
pound of plant origin. It was observed that this compound in pancreatic cancer cells 
induces apoptosis via the TRAIL pathway [29]. The expression level of XIAP may be 
subject to reduction under the influence of XIAP antisense oligonucleotides and with 
the participation of RNA interference (RNAi), the phenomenon of silencing on or off 
gene expression by RNA [22]. XIAP antisense oligonucleotides act on pancreatic can-
cer cells and cause the start of apoptosis with TRAIL pathway [30]. Acting on XIAP 
RNAi also can induce apoptosis after TRAIL treatment, anti CD95 or γ radiation [31], 
and also has the ability to suppress cell growth and proliferation of pancreatic cancer 
[22, 32]. Reduction of IAP protein expression in some pancreatic cancer cell lines was 
also observed after treatment with anticancer doxorubicin, cisplatin, gemcitabine [26, 33].
Mitochondrial pathway
Bcl-2 proteins are group of cellular oncogene products that regulate cell death process. 
The earliest discovered member of this group, from which the name is the anti-apop-
totic protein Bcl-2. Proteins of the Bcl-2 family have in common at least one of the 
four regions of homology domains called Bcl-2 (Bcl-2 homology domain — BH): BH1, 
BH2, BH3 and BH4. These domains determine the structure and function of these 
proteins [34]. The family of Bcl-2 antiapoptotic proteins include Bcl-2, Bcl-XL (B-cell 
lymphoma-extra large), MCL-1 (myeloid cell leukemia sequence 1) and proapoptotic 
(Bax, Bak, Bad, Bid) [11, 17]. A common cause of lack of efficacy of anticancer therapy 
is the overexpression of proteins with antiapoptotic properties and reduced expression 
of proapoptotic proteins (Fig. 2) [17]. 
High expression of Bcl-2 occurs in many types of cancer, but it does not deal with 
pancreatic cancer, where expression is normal or even weakly expressed [35]. In pancre-
atic cancer cells overexpression of Bcl-XL was observed which is the cause of resistance 
to apoptosis dependent Fas and TRAIL [36]. It was shown also that Bcl-XL expression 
correlates with survival. Patients with weak expression of Bcl-XL lived significantly longer 
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after tumor resection than those in whom there was even a moderate protein 
expression [37]. Therefore, Bcl-XL may be an ideal target in the treatment of pancreatic 
cancer [15]. 
There was a significant role of antisense oligonucleotides Bcl-XL, which inhibit the 
growth of pancreatic cancer cells, and cause the induction of apoptosis through decrease 
of Bcl-XL [15]. Bcl-XL antisense oligonucleotides also increase sensitivity to chemother-
apeutic agents such as gemcitabine [38].
 Proapoptotic proteins play important role in pancreatic cancer therapy. It was shown 
that pancreatic cancers that overexpress Bax have a greater sensitivity to gemcitabine [39]. 
Other studies have shown that increased levels of Bax and decrease Bcl-2 expression 
correlates with the exponentiation inhibitory effect of cisplatin in pancreatic cancer [40]. 
This means that the overexpression of Bax may be important in increasing the ther-
apeutic efficacy of chemotherapy. It should be stressed that overexpression of Bax 
in pancreatic cancer had no effect on the rate of apoptosis and the expression of Bcl-2 
and Bcl-XL [39, 40].
Another approach to targeting antiapoptotic Bcl-2 is the use of inhibitors. ABT-737 
Bcl-2 inhibitor sensitizes pancreatic cancer cells to apoptosis by stimulating the ex-
ternal and internal apoptotic pathways [22, 41]. An inhibitor of Bcl-2 TW-37 in-
hibits pancreatic cancer cell growth and tumor invasion and induces apoptosis [42]. 
Fig. 2. Effects causing pancreatic cancer and possible treatment options (modificated from Westphal and 
Kalthoff, 2003).
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High affinity for Bcl-XL shows ABT-263 inhibitor recently introduced for clinical 
trials. Reported data on the efficacy of this measure are promising. It is believed 
that it will be very effective in cancers characterized by overexpression of Bcl-2 or 
Bcl-XL [22, 41].
Other factors and signaling pathways could be a target  
for pancreatic cancer therapy
Nuclear factor of κβ (NF-κβ)
The transcription factor NF-κβ is regarded to be a factor increasing cell survival by acti-
vating antiapoptotic proteins. Normally present as an inactive complex in the cytoplasm. 
The variety of stimuli such as cytokines, oncogenes and stress can lead to its degradation 
and thus contribute to the activation of antiapoptotic genes and inhibition of apopto-
sis [43, 15]. It was shown that NF-κβ factor contributes to the inhibition of apoptosis 
in various tumor types including in patients with pancreatic cancer [15]. Therefore 
represents an important target in anticancer therapy. It was observed that inhibition 
of NF-κβ by MG 132 or sulfasalazine sensitizes pancreatic cancer cells to apoptosis 
induced by etoposide (VP16) or doxorubicin [44]. In addition, inhibition of nuclear 
factor by derivatives of polyphenols such as quercetin reduces the growth of cancer cells 
and prevents metastasis [45]. 
PI3K/Akt pathway 
In many tumor types including pancreatic cancers, occur proteins associated with the 
so-called antiapoptotic routes. Therefore, under the influence of apoptogenic signals re-
sponsible for cell survival signal is stronger than death. An example is the route related 
to the kinase Akt/PKB (PI3K phosphoinositide 3-kinase/AKT — also known as “protein 
kinase B”, PKB). The effect of protein kinase Akt/PKB is an inhibition of apoptosis and 
increased proliferation, including through the induction of NF-κβ, which ultimately leads 
to overexpression of antiapoptotic genes [14]. It has been shown to inhibit the kinase 
act through protein phosphorylation of Bad and caspase 9 and outflow of cytochrome 
c in a manner independent of phosphorylation of Bad. Also acts as a negative regula-
tor of transcription factors of the Forkhead family that can induce gene expression of 
proapoptotic proteins [46, 47]. Akt to its activation requires phosphorylation by PI3 
kinase. The tumor cells present often increased activity of PI3K kinase or Akt kinase 
[14, 15]. Strategies are implemented, which aim to block the enzymatic activity of PI3K 
and Akt / PKB. Wortmannin was found to be a potent inhibitor of PI3K. Treatment of 
cells of this compound led to the inhibition of proliferation and increasing apoptosis. 
In addition, wortmannin in combination with gemcitabine enhances apoptosis in vitro 
and in vivo in human pancreatic cancer cells [48].
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Mutations in the p53 gene
Important role in the uncontrolled proliferation and resistance to apoptosis in cancer 
cells, play p53 gene mutations [11]. Product of this gene acts as a regulator apoptotic 
program and coordinate this process at different levels. During apoptosis, the terms 
for the activation of p53, a transcription factor that is responsible for the expression 
of proapoptotic proteins by mitochondrial and by involving the death receptors [47].
Mutations in p53 are observed in 50% of various cancers, and in people healthy, they 
may serve as a marker of increased cancer risk. Pancreatic cancer cell lines showed mu-
tations in the p53 gene with a frequency of 95%. This affects the development and pro-
gression of cancer metastases. Therefore developed a number of methods based on gene 
therapy to normalize the function of p53 and inhibit the process of carcinogenesis [15].
Conclusions
The mechanisms involved in programmed cell death are crucial in understanding of 
cancer development and enable discovering of anti-cancer therapy. It is believed that 
the effectiveness of anticancer therapy is inhibition of cell proliferation and induction 
of apoptosis. Therefore, a better understanding of molecular mechanisms and signaling 
pathways that affect apoptosis may lead to the creation of a rational anticancer strategy 
that will contribute to the effective treatment of cancer patients. 
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